University Academic Fellow & Hepatologist at University of Leeds. Interested in liver disease and treatment of cirrhosis and HCC. Views my own.
May 21, 2020 • 5 tweets • 3 min read
Thanks to recent data releases from @ONS I think we can be a little clearer about the excess "non-COVID" mortality in England and Wales
1. Deaths of Care Home residents in hospital were more likely to be registered as related to COVID than those in care homes
...
1/n 2. Levels of in hospital mortality in Care Home residents have not substantially increase despite increased illness and overall mortality
3. Nor do they seem to account for the displacement of in hospital mortality into the community observed by @d_spiegel and others
...
2/n
May 13, 2020 • 16 tweets • 7 min read
What can patients with #NASH expect from clinical trials?
Recent negative results from $GILD and now $GNFT in Phase 3 highlight the uncertainties entering trials that patients face
Is there a minimum potential benefit a patient should accept when entering a trial?
THREAD
In Phase 3, participants with #NASH entering a trial there is no certainty that the drug being tested will work and they are taking a risk with a new treatment
Is there a minimum threshold for benefit in a trial that participants might expect?
2/n